Cyclo Therapeutics Inc.
(CYTHW)
undefined
undefined%
At close: undefined
0.00
-100.00%
After-hours Dec 31, 1969, 07:00 PM EST
Company Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease.
Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease.
The company was founded by Charles E.
Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Cyclo Therapeutics Inc.
| Country | United States |
| IPO Date | Dec 18, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | N. Scott Fine |
Contact Details
Address: No Address available No city data available, United States | |
| Website | http://www.cyclotherapeutics.com |
Stock Details
| Ticker Symbol | CYTHW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0000922247 |
| CUSIP Number | 23254X110 |
| ISIN Number | US23254X1101 |
| Employer ID | 59-3029743 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| N. Scott Fine | Chief Executive Officer & Director |
| Dr. Jeffrey L. Tate Ph.D. | Chief Operating Officer, Chief Quality Officer & Director |
| Joshua M. Fine | Chief Financial Officer & Secretary |
| C. E Strattan | Founder & Director |
| Dr. Karen Mullen FFPM | Interim Chief Medical Officer |
| Lori McKenna | Global Head of Patient Advocacy |
| Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 05, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 10-K/A | [Amend] Annual Report |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 18, 2024 | 4 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |